Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Monday . The stock had previously closed at $79.15, but opened at $74.8782. Zealand Pharma A/S shares last traded at $74.8782, with a volume of 215 shares trading hands.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ZLDPF. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Wells Fargo & Company raised Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. Finally, Barclays upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Monday, July 7th. Five investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Zealand Pharma A/S Stock Performance

The business has a 50 day moving average price of $72.21 and a 200 day moving average price of $65.31. The stock has a market cap of $5.32 billion, a P/E ratio of 5.26 and a beta of 0.74. The company has a quick ratio of 15.08, a current ratio of 15.09 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%.The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $9.18 billion. As a group, sell-side analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.